GB0225030D0 - Medicinal compounds - Google Patents

Medicinal compounds

Info

Publication number
GB0225030D0
GB0225030D0 GB0225030A GB0225030A GB0225030D0 GB 0225030 D0 GB0225030 D0 GB 0225030D0 GB 0225030 A GB0225030 A GB 0225030A GB 0225030 A GB0225030 A GB 0225030A GB 0225030 D0 GB0225030 D0 GB 0225030D0
Authority
GB
United Kingdom
Prior art keywords
medicinal compounds
medicinal
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0225030A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0225030A priority Critical patent/GB0225030D0/en
Publication of GB0225030D0 publication Critical patent/GB0225030D0/en
Application status is Ceased legal-status Critical

Links

GB0225030A 2002-10-28 2002-10-28 Medicinal compounds Ceased GB0225030D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0225030A GB0225030D0 (en) 2002-10-28 2002-10-28 Medicinal compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0225030A GB0225030D0 (en) 2002-10-28 2002-10-28 Medicinal compounds
PCT/EP2003/012038 WO2004037768A2 (en) 2002-10-28 2003-10-24 Phenethanolamine derivatives
AU2003293632A AU2003293632A1 (en) 2002-10-28 2003-10-24 Phenethanolamine derivatives

Publications (1)

Publication Number Publication Date
GB0225030D0 true GB0225030D0 (en) 2002-12-04

Family

ID=9946704

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0225030A Ceased GB0225030D0 (en) 2002-10-28 2002-10-28 Medicinal compounds

Country Status (3)

Country Link
AU (1) AU2003293632A1 (en)
GB (1) GB0225030D0 (en)
WO (1) WO2004037768A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507881A (en) 2001-09-17 2005-03-24 グラクソ グループ リミテッドGlaxo Group Limited Dry powder pharmaceutical formulation
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
PE20060272A1 (en) 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4's, 5'S) -2,2 '- {trans-1,4-ciclohexanodiilbis- [imino (2 - {[2- (1-methyl- 1H-imidazol-4-yl) ethyl amino]} -9 H -purine-6,9-diyl)]} bis [5- (2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandiol] a2a agonist
AU2005252226A1 (en) 2004-06-03 2005-12-22 Theravance, Inc. Diamine beta2 adrenergic receptor agonists
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag organic compounds.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd new compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200811111A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Novel compounds
DK2013211T3 (en) 2006-04-21 2012-07-02 Novartis Ag Purine derivatives for use as adenosine A2A receptor agonists
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AR061571A1 (en) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compound of the toluenesulfonic acid salt of 4 - {[6-chloro-3 - ({[(2-chloro-3-fluorophenyl) amino carbonyl] amino}) - 2- hydroxyphenyl] sulfonyl] -1- piperazinacarbxilato 1.1-dimethylethyl pharmaceutical composition comprising the use for the manufacture of a medicament a pharmaceutical combination
CA2659539A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. Compounds and compositions as channel activating protease inhibitors
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp Carboxamide indole compound, pharmaceutical composition comprising the same and use of said compound for preparing a medicament
CA2685546A1 (en) 2007-05-07 2008-11-13 Novartis Ag Organic compounds
EP2520574A1 (en) 2007-12-10 2012-11-07 Novartis AG Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases
MX2010007604A (en) 2008-01-11 2010-08-02 Novartis Ag Pyrimidines as kinase inhibitors.
MX2010012814A (en) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc 5-lipoxygenase-activating protein inhibitor.
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SI2379507T1 (en) 2008-12-30 2014-02-28 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
JP2012520257A (en) 2009-03-10 2012-09-06 グラクソ グループ リミテッドGlaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
US20120016010A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521762A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of nerve growth factor β chain (NGFβ) gene expression using small interfering nucleic acids (siNA)
KR20110138223A (en) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120035237A1 (en) 2009-04-24 2012-02-09 Diane Mary Coe Pyrazole and triazole carboxamides as crac chann el inhibitors
EP2421835A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
RS56433B1 (en) 2009-04-30 2018-01-31 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
JP2013512880A (en) 2009-12-03 2013-04-18 グラクソ グループ リミテッドGlaxo Group Limited Indazole derivatives as PI3-kinase inhibitors
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2532213T3 (en) 2010-10-21 2015-03-25 Glaxo Group Limited Pyrazole compounds that act against allergic, immune and inflammatory conditions
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP5886433B2 (en) 2011-09-16 2016-03-16 ノバルティス アーゲー Heterocyclic compounds for the treatment of cystic fibrosis
JP6165733B2 (en) 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA032075B1 (en) 2014-04-24 2019-04-30 Новартис Аг Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CR20160529A (en) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd pharmaceutical compositions for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB2230525A (en) * 1989-04-14 1990-10-24 Glaxo Group Ltd 1-(Hydroxyphenyl)-2-aminoethanol derivatives
AU1533495A (en) * 1994-01-12 1995-08-01 Byk Nederland Bv Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists

Also Published As

Publication number Publication date
WO2004037768A2 (en) 2004-05-06
AU2003293632A1 (en) 2004-05-13
AU2003293632A8 (en) 2004-05-13
WO2004037768A3 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
TWI341314B (en) New compounds
EG27104A (en) Pharmaceutical compounds
GB0224084D0 (en) Novel compounds
GB0228410D0 (en) Novel Compounds
GB0217757D0 (en) Novel compounds
GB0218630D0 (en) Novel compounds
GB0202216D0 (en) Novel compounds
GB0306328D0 (en) Novel compounds
GB0209891D0 (en) Novel compounds
IL177933D0 (en) New compounds
IL166650D0 (en) New compounds
PL372799A1 (en) New compounds
AU2003264018A8 (en) New compounds
GB0210397D0 (en) Pharmaceutical formulations
GB0225287D0 (en) Novel compounds
GB0225944D0 (en) Novel compounds
PL372966A1 (en) New compounds
HRP20041152A2 (en) Pharmaceutical formulations
GB0208587D0 (en) Capsules
GB0230045D0 (en) Compounds
GB0206860D0 (en) Compounds
GB0226593D0 (en) Compounds
GB0226583D0 (en) Compounds
GB0208279D0 (en) Novel compounds
GB0222495D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)